EuroClonality-NDC
Why settle for less
when you can have it all?
Our first product, the EuroClonality-NDC assay allows you to detect immunoglobulin (IG) and T-cell receptor (TR) rearrangements and translocations, as well as mutations and copy number alterations in clinically relevant genes for most lymphoproliferative disorders.
EuroClonality-NDC has been designed and developed by the EuroClonality-NGS working group (an independent subdivision of EuroClonality) and validated in a multi-centre international study involving expert clinical and academic laboratories across Europe.
Request a quotation
What our customers say
Composition of EuroClonality-NDC assay
The EuroClonality-NDC assay contains a series of genomic regions covering all the IG (including IGH switch regions) and TR genes, intronic regions of some commonly translocated genes, coding regions of clinically-relevant genes and specific regions for copy number variation (CNV) analysis.
List of genes with full coding regions mutation assessment on EuroClonality-NDC
| ARID1A | EP300 | MAP3K14 | SAMHD1 |
| ATM | ERG | MAPK1 | SOCS1 |
| B2M | FAT1 | MYC | TCF3 |
| BCL2 | H1-5 | PAX5 | TENT5C |
| BTG1 | H1-2 | PHF6 | TET2 |
| BTK | H1-3 | POT1 | TNFAIP3 |
| CDKN2A | H1-4 | PTEN | TP53 |
| CDKN2B | ID3 | PTPRD | TRAF2 |
| CDKN2C | KLF2 | RHOA | TRAF3 |
| CKS1B | KMT2D | RUNX1 | WT1 |
List of genes with select regions for mutation assessment on EuroClonality-NDC
Additional Regions & Additional Chromosome Regions Assessed
Performance of the EuroClonality-NDC assay
The expected metrics for library preparation and hybridisation performance ensure sufficient coverage of all targets to obtain robust and reliable results.
Analytical sensitivity varies according to the type of alterations, from >95% for CNV up to >99% for sequence variants at >4% VAF. Analytical specificity also varies from >97% for CNV and IG/TR rearrangements up to >99% for sequence variants at >4% VAF.
Download Quick Reference and Analysis GuidesExpected metrics & Analytical Performance
EuroClonality-NDC CNV output for IG, TR and clinically relevant genes in cell line RS4;11
The EuroClonality-NDC assay produces copy number variant (CNV) outputs specifically for IG and TR rearrangements that can be used alongside the Rearrangement results to assess clonality in an orthogonal fashion. These CNV plots are most helpful when the tumour content is at least 40%. There is also an additional output (called ’Onco’) that shows CNV data across a range of clinically relevant genes and genomic regions included in the assay. CNV data have been validated for high molecular weight DNA samples containing more than 40% tumour cells.
Download examples of results produced by the EuroClonality-NDC assay
EuroClonality-NDC Copy number alteration plots in clinical samples
Clinical and academic centres involved in the EuroClonality-NDC validation
| Queen’s University Belfast | Belfast, UK |
| Universitätsklinikum Schleswig-Holstein (UKSH) | Kiel, GERMANY |
| CEITEC – Central European Technology Institute | Brno, CZECH REPUBLIC |
| The Royal Marsden NHS Trust | London, UK |
| Centro Maria Letizia Verga | Monza, ITALY |
| Hospital Universitario de Salamanca | Salamanca, SPAIN |
| Hopital Necker-Enfants Malades | Paris, FRANCE |
| Erasmus MC, university medical center Rotterdam | Rotterdam, THE NETHERLANDS |
| Centre for Research and Technology Hellas | Thessaloniki, GREECE |
| University of Torino | Torino, ITALY |
| Radboud university medical centre Nijmegen | Nijmegen, THE NETHERLANDS |
| Hopital Pitié-Salpétrière | Paris, FRANCE |
